Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

The US Department of Health and Human Services has planned to cancel $500 million in funding for mRNA vaccines, citing ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.

The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...